Anti-TNF treatment in Crohn's disease: toward tailored therapy?
- PMID: 20445512
- DOI: 10.1038/ajg.2010.15
Anti-TNF treatment in Crohn's disease: toward tailored therapy?
Abstract
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
Comment on
-
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.Am J Gastroenterol. 2010 May;105(5):1133-9. doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9. Am J Gastroenterol. 2010. PMID: 20145610 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
